Edesa biotech announces $15.0 million private placement priced at-the-market under nasdaq rules

Toronto, feb. 13, 2025 (globe newswire) -- edesa biotech, inc. (nasdaq: edsa) (the “company” or “edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement, an aggregate of 834 newly designated series b-1 convertible preferred shares (“series b-1 preferred shares”) and 3,468,746 common shares in a private placement priced at-the-market under the rules of the nasdaq stock market. the purchase price per preferred share was $10,000 and the purchase price per common share was $1.92. officers and directors of the company purchased approximately $1.1 million of the securities sold in the offering.
NDAQ Ratings Summary
NDAQ Quant Ranking